145851-04-3

Basic information

• Product Name: (4-nitrophenyl)(piperidin-4-yl)methanone
• Synonyms: (4-nitrophenyl)(piperidin-4-yl)methanone
• CAS NO: 145851-04-3
• Molecular Weight: 234.255
• Mol File: 145851-04-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (4-nitrophenyl)(piperidin-4-yl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (4-nitrophenyl)(piperidin-4-yl)methanone(145851-04-3)
• EPA Substance Registry System: (4-nitrophenyl)(piperidin-4-yl)methanone(145851-04-3)

Safety Data

• Hazardous Substances Data: 145851-04-3(Hazardous Substances Data)

Usage

Description

(4-nitrophenyl)(piperidin-4-yl)methanone, also known as NPCP, is a yellow crystalline powder with a molecular formula C16H18N2O3. It is a chemical compound belonging to the class of piperidine derivatives, commonly used in organic synthesis and medicinal chemistry as a building block for the synthesis of various pharmaceutical compounds. NPCP has also been studied for its potential pharmacological activities, including its role as an analgesic and anti-inflammatory agent, as well as its potential use in the treatment of neurological disorders and as a precursor for the development of novel drugs.

Uses

Used in Pharmaceutical Industry:
NPCP is used as a building block for the synthesis of various pharmaceutical compounds due to its versatile chemical structure and potential pharmacological activities.
Used in Medicinal Chemistry:
NPCP is used as a starting material for the development of novel drugs, particularly in the areas of analgesics, anti-inflammatory agents, and treatments for neurological disorders.
Used in Organic Synthesis:
NPCP is used as a key intermediate in the synthesis of complex organic molecules, contributing to the development of new chemical entities with potential applications in various fields.
It is important to handle NPCP with care, as it is toxic and can cause irritation to the skin, eyes, and respiratory system.

Upstream product

• 1126087-92-0 (1-benzoylpiperidin-4-yl)(4-bromophenyl)methanone 
• 1126-09-6 4-carbethoxypiperidine 
• 136081-74-8 ethyl 1-benzoyl-4-piperidine-carboxylate 
• 115755-50-5 1-benzoyl-4-piperidinecarbonyl chloride 
• 5274-99-7 1-benzoylisonipecotic acid 
• 115755-53-8 (1-benzoylpiperidin-4-yl)(4-nitrophenyl)methanone 

Downstream Products

• 1310689-21-4 [1-(5-methoxybenzimidazol-2-ylmethyl)piperidin-4-yl]-(4-nitrophenyl)methanone 
• 1310689-32-7 4-(4-⁽¹⁸⁾F-fluorobenzyl)piperidine 
• 1310689-31-6 tert-butyl 1-[4-(4-⁽¹⁸⁾F-fluorobenzoyl)piperidin-1-yl]carboxylate 
• 1310689-28-1 2-[4-(4-⁽¹⁸⁾F-fluorobenzyl)piperidin-1-ylmethyl]benzimidazol-5-ol 
• 1310689-27-0 2-[4-(4-⁽¹⁸⁾F-fluorobenzyl)piperidin-1-yl]methyl-5-methoxybenzimidazole 
• 1310689-26-9 [1-(5-methoxybenzimidazol)-2-ylmethylpiperidin-4-yl]-(4-⁽¹⁸⁾F-fluorophenyl)methanone 
• 228852-06-0 ethyl N-(2-(4-(4-nitrobenzoyl)piperidin-1-yl)ethyl-2,2-d2)carbamate 

Relevant articles and documents

Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT7)/5-Hydroxytryptamine 2A (5-HT2A) Receptor Antagonists and Evaluation by [18F]-PET Imaging in a Primate Brain

We report the synthesis of 46 tertiary amine-bearing N-alkylated benzo[d]imidazol-2(3H)-ones, imidazo[4,5-b]pyridin-2(3H)-ones, imidazo[4,5-c]pyridin-2(3H)-ones, benzo[d]oxazol-2(3H)-ones, oxazolo[4,5-b]pyridin-2(3H)-ones and N,N′-dialkylated benzo[d]imidazol-2(3H)-ones. These compounds were evaluated against 5-HT7R, 5-HT2AR, 5-HT1AR, and 5-HT6R as potent dual 5-HT7/5-HT2A serotonin receptors ligands. A thorough study of the structure-activity relationship of the aromatic rings and their substituents, the alkyl chain length and the tertiary amine was conducted. 1-(4-(4-(4-Fluorobenzoyl)piperidin-1-yl)butyl)-1H-benzo[d]imidazol-2(3H)-one (79) and 1-(6-(4-(4-fluorobenzoyl)piperidin-1-yl)hexyl)-1H-benzo[d]imidazol-2(3H)-one (81) were identified as full antagonist ligands on cyclic adenosine monophosphate (cAMP, KB = 4.9 and 5.9 nM, respectively) and inositol monophosphate (IP1, KB = 0.6 and 16 nM, respectively) signaling pathways of 5-HT7R and 5-HT2AR. Both antagonists crossed the blood-brain barrier as evaluated with [18F] radiolabeled compounds [18F]79 and [18F]81 in a primate's central nervous system using positron emission tomography. Both radioligands showed standard uptake values ranging from 0.8 to 1.1, a good plasmatic stability, and a distribution consistent with 5-HT7R and 5-HT2AR in the CNS.

Application of the Deuterium Isotope Effect to Enhance PET Signal by Impeding Tracer Metabolism: Synthesis of Deuterium and Fluorine-18 Duallabeled Altanserin and Its Nitro-Precursor

-